⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
One of the most common frustrations among Indian GLP-1 users is not understanding what "progress" actually looks like. The scale stops moving for two weeks and people panic. HbA1c improves but weight is unchanged, and they wonder if the medication is working. A friend loses 8 kg in two months; another loses 3 kg in the same period on the same drug — and both are having a normal response.
This guide explains what to track, what to ignore, realistic timelines based on clinical trial data, and why Indian bodies require different benchmarks than those used in Western clinical settings.
Consult your healthcare provider before starting any medication or making major dietary changes.
Traditional dieting is binary: you either lost weight or you did not. GLP-1 therapy is different because the medication simultaneously affects:
Tracking only body weight misses most of the picture. Many GLP-1 users see enormous health improvements — HbA1c down from 9% to 6.5%, liver enzymes normalised, blood pressure off medication — while weight loss is slower than expected.
Body weight
Blood pressure (if you have hypertension)
Waist circumference
Waist-to-height ratio
Food diary review
HbA1c (if diabetic or pre-diabetic)
Fasting blood sugar and postprandial glucose (PPBS)
Lipid panel
Liver enzymes (ALT, AST)
Kidney function (creatinine, eGFR, urine microalbumin)
Full blood count, iron, ferritin, B12, D3
Standard WHO BMI thresholds (overweight ≥25, obese ≥30) underestimate metabolic risk in South Asians. Indian-specific thresholds endorsed by ICMR and the Research Society for the Study of Diabetes in India (RSSDI):
| Category | Standard WHO BMI | Indian / South Asian BMI |
|---|---|---|
| Normal weight | 18.5–24.9 | 18.5–22.9 |
| Overweight | 25–29.9 | 23–24.9 |
| Obese (Class I) | 30–34.9 | 25–29.9 |
| Obese (Class II) | ≥35 | ≥30 |
What this means for you: If your BMI is 26 and your doctor says "you are not obese enough to worry," they may be using the wrong threshold. Indians develop type 2 diabetes, hypertension, and metabolic syndrome at much lower BMI values than European populations.
| Timeframe | Semaglutide 2.4 mg (STEP 1 trial) | Tirzepatide 15 mg (SURMOUNT-1 trial) |
|---|---|---|
| 4 weeks | ~2–4% body weight loss | ~2–4% body weight loss |
| 12 weeks | ~5–8% body weight loss | ~6–10% body weight loss |
| 6 months | ~8–13% body weight loss | ~12–18% body weight loss |
| 12 months | ~12–17% body weight loss | ~18–24% body weight loss |
| Final (68–72 weeks) | ~15% average | ~20–22% average |
Indian context: Most Indian patients are on lower doses (0.5 mg or 1 mg semaglutide, or tirzepatide 5 mg) than maximum trial doses due to affordability and tolerability. Expect modestly lower percentage losses at Indian therapeutic doses.
These are often more meaningful than the number on the scale:
| Tool | What It Tracks | Available in India? |
|---|---|---|
| HealthifyMe | Weight, food diary, calories, Indian nutrition data | Yes — Indian-specific food database |
| OneTouch Reveal | Blood glucose, patterns, insulin logs | Yes (OneTouch devices) |
| Accu-Chek Connect | Blood glucose, insulin dose tracking | Yes (Accu-Chek devices) |
| Ayushman Bharat Health Account (ABHA) | Unified health records | Yes (Government of India) |
| Google Fit | Steps, weight, heart rate | Yes |
| Apple Health | Comprehensive health metrics | Yes (iPhone) |
| Cronometer | Detailed micronutrient tracking | Yes (web + app) |
Weighing daily. Water weight fluctuates 1–2 kg every day from salt intake, menstrual cycle, bowel movement, and hydration. Daily weighing creates anxiety without meaningful information. Weekly averages are informative; daily numbers rarely are.
Comparing your progress to others. GLP-1 response varies enormously by baseline weight, insulin resistance severity, gut microbiome composition, and dose. A social media story of dramatic weight loss may not — and usually is not — typical.
Stopping medication during a plateau. Weight loss plateaus are expected and do not mean the drug has failed. Plateau strategies include dose optimisation, diet audit, and exercise changes — not stopping the medication.
Judging success only by weight. A 5% weight loss with HbA1c dropping from 9% to 6.5% is a major medical success, even if the absolute weight lost seems modest to you.
Q: How long before I see meaningful weight loss? Most people see 3–5% weight loss in the first 4–8 weeks. If there is no change after 12 weeks at an effective dose, discuss dose optimisation with your doctor.
Q: My weight has not moved in 3 weeks. Should I stop? No. Plateaus of 2–4 weeks are normal, especially during dose escalation. Track waist circumference — sometimes fat is being lost even when scale weight is stable because muscle gained through activity partially offsets fat loss.
Q: Which blood tests should I get before starting GLP-1? Minimum: HbA1c, fasting glucose, lipid panel, kidney function (creatinine, eGFR), liver enzymes (ALT/AST), TSH, full blood count. Your doctor will advise based on your specific history.
Q: Is there an Indian clinical monitoring protocol for GLP-1? Yes. The RSSDI (Research Society for the Study of Diabetes in India) recommends HbA1c monitoring every 3 months and renal function annually for diabetic patients on GLP-1 therapy.
Consult your healthcare provider before starting any medication or making major dietary changes.
